Last reviewed · How we verify
Clomiphene citrate / hCG
Clomiphene citrate stimulates gonadotropin release to promote ovulation, while hCG triggers final oocyte maturation and ovulation.
Clomiphene citrate stimulates gonadotropin release to promote ovulation, while hCG triggers final oocyte maturation and ovulation. Used for Anovulation and infertility in women undergoing assisted reproductive technology (ART), Controlled ovarian hyperstimulation for in vitro fertilization (IVF).
At a glance
| Generic name | Clomiphene citrate / hCG |
|---|---|
| Also known as | Clomid / choriomon |
| Sponsor | The Egyptian IVF-ET Center |
| Drug class | Ovulation induction agent / Gonadotropin-releasing hormone analog combination |
| Target | Estrogen receptor (clomiphene); LH receptor (hCG) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Clomiphene citrate is a selective estrogen receptor modulator that blocks negative feedback of estrogen on the hypothalamic-pituitary axis, increasing FSH and LH secretion to stimulate follicle development. Human chorionic gonadotropin (hCG) is then administered to mimic the LH surge, triggering final oocyte maturation and ovulation. This combination is used in assisted reproductive technology protocols to control the timing and synchronization of ovulation.
Approved indications
- Anovulation and infertility in women undergoing assisted reproductive technology (ART)
- Controlled ovarian hyperstimulation for in vitro fertilization (IVF)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Hot flashes
- Abdominal bloating and discomfort
- Nausea
- Visual disturbances
- Headache
Key clinical trials
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- LE + CC vs. LE for Ovulation Induction (NA)
- One-shot Ovarian Stimulation Protocol (One-shot) (NA)
- Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (PHASE3)
- Cost-effective Treatment of Unexplained Infertility (PHASE4)
- Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders (EARLY_PHASE1)
- Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women (PHASE3)
- Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clomiphene citrate / hCG CI brief — competitive landscape report
- Clomiphene citrate / hCG updates RSS · CI watch RSS
- The Egyptian IVF-ET Center portfolio CI